DCAL Reports Q2 Revenue Of ₹507 Crore Versus ₹653 Crore YoY

Market snapshot: Dishman Carbogen Amcis Limited reported consolidated Q2 revenue of ₹507 crore, compared to ₹653 crore in the corresponding period of the previous year. The performance reflects a 22.36% decline in top-line revenue year-on-year.

Data Snapshot

• Q2 revenue stood at ₹507 crore compared to ₹653 crore in the year-ago quarter, marking a YoY contraction of 22.36%.
• Prior year Q2 consolidated top-line reached ₹652.65 crore, providing the comparative baseline for the reported performance.

What's Changed

• Consolidated quarterly revenue contracted from ₹653 crore in Q2 of the previous year to ₹507 crore.
• Top-line growth declined by ≈22.36% YoY (derived: ₹507 cr vs ₹653 cr).

Key Takeaways

• Dishman Carbogen Amcis reported Q2 revenue of ₹507 crore, down 22.36% from ₹653 crore YoY.
• The top-line contraction reflects quarterly variance within its Contract Research and Manufacturing Services (CRAMS) operations.
• Prior period comparative revenue of ₹652.65 crore establishes the baseline for the year-on-year revenue reduction.

SAHI Perspective

The top-line contraction for Dishman Carbogen Amcis points to operational campaign shifts in key contract development and manufacturing schedules. Investors should monitor batch execution rates and capacity utilization across global facilities.

Market Implications

Near-term trading sentiment for DCAL may reflect top-line contraction risks, with market attention shifting toward profitability preservation and order book execution across upcoming quarters.

Trading Signals

Market Bias: Bearish

Bias is Bearish following a 22.36% year-on-year revenue decline to ₹507 crore from ₹653 crore in Q2, indicating operational top-line pressure in contract manufacturing operations.

Underweight: Pharmaceuticals CRAMS / CDMO

Trigger Factors:

• Q2 revenue decline to ₹507 crore vs ₹653 crore YoY
• Management update on order book replenishment and campaign execution
• Detailed segment margin disclosures in full quarterly filings

Time Horizon: Near-term (0-3 months)

Industry Context

Contract Research and Manufacturing Services (CRAMS) companies experience quarterly revenue variance driven by commercial batch delivery schedules, phase transitions in clinical candidates, and client inventory optimization cycles across active pharmaceutical ingredients.

Key Risks to Watch

• Delays in clinical phase campaign deliveries or commercial batch shipments
• Fixed overhead pressure on operating margins during lower revenue periods
• Foreign exchange rate fluctuations across European operating subsidiaries

Recent Developments

In May 2026, DCAL submitted transcripts for its annual earnings conference call detailing business performance across CRAMS and marketable molecules divisions.

Closing Insight

Monitoring execution timelines in phase III drug substance projects will be key to evaluating potential top-line recovery in upcoming quarters.

High Performance Trading with SAHI.